Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer.


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
11 2020
Historique:
received: 01 05 2020
revised: 12 06 2020
accepted: 23 06 2020
pubmed: 1 7 2020
medline: 13 11 2020
entrez: 30 6 2020
Statut: ppublish

Résumé

The coronavirus disease 2019 pandemic has resulted in unprecedented challenges for the oncology community. For people living with cancer, treatments are interrupted, surgeries cancelled, and regular oncology evaluations rescheduled. People with cancer and their physicians must balance plausible fears of coronavirus disease 2019 and cancer treatment with the consequences of delaying cancer care. We aim to evaluate the experience of women with ovarian cancer during the coronavirus disease 2019 pandemic. Women with a current or previous diagnosis of ovarian cancer completed an online survey focusing on treatment interruptions and quality of life. The quality of life was measured with the Cancer Worry Scale and Hospital Anxiety and Depression Scale. The survey was distributed through survivor networks and social media. Univariate and multivariable linear regression analysis were used to evaluate the effect of participant characteristics on quality of life survey scores. A total of 603 women, from 41 states, visited the survey website between March 30, 2020, and April 13, 2020, and 555 (92.0%) completed the survey. The median age was 58 years (range, 20-85). At the time of survey completion, 217 participants (43.3%) were in active treatment. A total of 175 participants (33%) experienced a delay in some component of their cancer care. Ten (26.3%) of the 38 participants scheduled for surgery experienced a delay, as did 18 (8.3%) of the 217 participants scheduled for nonsurgical cancer treatment. A total of 133 participants (24.0%) had a delayed physician appointment, 84 (15.1%) laboratory tests, and 53 (9.6%) cancer-related imaging. Among the cohort, 88.6% (489) reported significant cancer worry, 51.4% (285) borderline or abnormal anxiety, and 26.5% (147) borderline or abnormal depression. On univariate analysis, age less than 65 years, being scheduled for cancer treatment or cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine were all associated with higher levels of cancer worry. Higher anxiety scores were associated with age less than 65 years and being self-described as immunocompromised. Higher depression scores were associated with age less than 65 years, being scheduled for cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine. On multivariable linear regression analysis, age less than 65 and being self-described as immunocompromised were independently predictive of greater cancer worry, anxiety, and depression, and delay in cancer care was predictive of anxiety and depression. The coronavirus disease 2019 crisis is affecting care of patients with ovarian cancer; surgeries, treatments, scheduled physician appointments, laboratory tests, and imaging are cancelled or delayed. Younger age, presumed immunocompromise, and delay in cancer care were associated with significantly higher levels of cancer worry, anxiety, and depression. Providers must work with patients to balance competing risks of coronavirus disease 2019 and cancer, recognizing that communication is a critical clinical tool to improve quality of life in these times.

Sections du résumé

BACKGROUND
The coronavirus disease 2019 pandemic has resulted in unprecedented challenges for the oncology community. For people living with cancer, treatments are interrupted, surgeries cancelled, and regular oncology evaluations rescheduled. People with cancer and their physicians must balance plausible fears of coronavirus disease 2019 and cancer treatment with the consequences of delaying cancer care.
OBJECTIVE
We aim to evaluate the experience of women with ovarian cancer during the coronavirus disease 2019 pandemic.
STUDY DESIGN
Women with a current or previous diagnosis of ovarian cancer completed an online survey focusing on treatment interruptions and quality of life. The quality of life was measured with the Cancer Worry Scale and Hospital Anxiety and Depression Scale. The survey was distributed through survivor networks and social media. Univariate and multivariable linear regression analysis were used to evaluate the effect of participant characteristics on quality of life survey scores.
RESULTS
A total of 603 women, from 41 states, visited the survey website between March 30, 2020, and April 13, 2020, and 555 (92.0%) completed the survey. The median age was 58 years (range, 20-85). At the time of survey completion, 217 participants (43.3%) were in active treatment. A total of 175 participants (33%) experienced a delay in some component of their cancer care. Ten (26.3%) of the 38 participants scheduled for surgery experienced a delay, as did 18 (8.3%) of the 217 participants scheduled for nonsurgical cancer treatment. A total of 133 participants (24.0%) had a delayed physician appointment, 84 (15.1%) laboratory tests, and 53 (9.6%) cancer-related imaging. Among the cohort, 88.6% (489) reported significant cancer worry, 51.4% (285) borderline or abnormal anxiety, and 26.5% (147) borderline or abnormal depression. On univariate analysis, age less than 65 years, being scheduled for cancer treatment or cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine were all associated with higher levels of cancer worry. Higher anxiety scores were associated with age less than 65 years and being self-described as immunocompromised. Higher depression scores were associated with age less than 65 years, being scheduled for cancer surgery, delay in oncology care, being self-described as immunocompromised, and use of telemedicine. On multivariable linear regression analysis, age less than 65 and being self-described as immunocompromised were independently predictive of greater cancer worry, anxiety, and depression, and delay in cancer care was predictive of anxiety and depression.
CONCLUSION
The coronavirus disease 2019 crisis is affecting care of patients with ovarian cancer; surgeries, treatments, scheduled physician appointments, laboratory tests, and imaging are cancelled or delayed. Younger age, presumed immunocompromise, and delay in cancer care were associated with significantly higher levels of cancer worry, anxiety, and depression. Providers must work with patients to balance competing risks of coronavirus disease 2019 and cancer, recognizing that communication is a critical clinical tool to improve quality of life in these times.

Identifiants

pubmed: 32598911
pii: S0002-9378(20)30674-8
doi: 10.1016/j.ajog.2020.06.049
pmc: PMC7318934
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

725.e1-725.e9

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Aust N Z J Obstet Gynaecol. 2009 Dec;49(6):660-6
pubmed: 20070719
Br J Health Psychol. 2004 Nov;9(Pt 4):569-81
pubmed: 15509362
Psychooncology. 2015 Feb;24(2):190-6
pubmed: 25044162
J Natl Compr Canc Netw. 2016 Apr;14(4):429-37
pubmed: 27059191
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Psychooncology. 2018 Jul;27(7):1810-1815
pubmed: 29644766
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Nat Med. 2020 Apr;26(4):458
pubmed: 32284617
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Gynecol Oncol. 2014 Nov;135(2):261-5
pubmed: 25230215
Med J Aust. 2010 Sep 6;193(S5):S52-7
pubmed: 21542447
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Racial Ethn Health Disparities. 2020 Jun;7(3):398-402
pubmed: 32306369
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Gynecol Oncol. 2017 Aug;146(2):386-391
pubmed: 28602549
Health Aff (Millwood). 2013 Jun;32(6):1143-52
pubmed: 23676531
Asia Pac J Oncol Nurs. 2015 Jul-Sep;2(3):160-168
pubmed: 27981110
Psychooncology. 2018 Nov;27(11):2609-2615
pubmed: 29843189
J Clin Oncol. 1994 Apr;12(4):843-50
pubmed: 8151327
J Clin Oncol. 2020 Jul 1;38(19):2206-2207
pubmed: 32267782
JCO Oncol Pract. 2020 Feb;16(2):e148-e154
pubmed: 31815575
Gynecol Oncol. 2020 Jul;158(1):25-31
pubmed: 32446719
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
Obstet Gynecol. 2017 Dec;130(6):1269-1275
pubmed: 29112648
Nat Commun. 2017 Jul 11;8:15964
pubmed: 28696410
J Natl Compr Canc Netw. 2017 Jul;15(7):872-877
pubmed: 28687575
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:85-91
pubmed: 28738296
Gynecol Oncol. 2007 Feb;104(2):381-9
pubmed: 17027072
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Gynecol Oncol. 2020 Jul;158(1):32-33
pubmed: 32402631
Eur J Cancer Care (Engl). 2007 Jan;16(1):33-8
pubmed: 17227351
J Psychosom Obstet Gynaecol. 2016;37(2):57-67
pubmed: 26939616

Auteurs

Melissa K Frey (MK)

Weill Cornell Medicine, New York, NY. Electronic address: mkf2002@med.cornell.edu.

Annie E Ellis (AE)

Ovarian Cancer Research Alliance, New York, NY; SHARE, New York, NY.

Kristen Zeligs (K)

Icahn School of Medicine at Mount Sinai, New York, NY.

Eloise Chapman-Davis (E)

Weill Cornell Medicine, New York, NY.

Charlene Thomas (C)

Weill Cornell Medicine, New York, NY.

Paul J Christos (PJ)

Weill Cornell Medicine, New York, NY.

Valentin Kolev (V)

Icahn School of Medicine at Mount Sinai, New York, NY.

Monica Prasad-Hayes (M)

Icahn School of Medicine at Mount Sinai, New York, NY.

Samantha Cohen (S)

Icahn School of Medicine at Mount Sinai, New York, NY.

Kevin Holcomb (K)

Weill Cornell Medicine, New York, NY.

Stephanie V Blank (SV)

Blavatnik Family Women's Health Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH